TKI can compete with ATP or substrate, specifically inhibit the tyrosine kinase activity of BCR/ABL, and imatinib is now the first-line therapy for chronic-phase CML [42]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.